BTIG analyst David Larsen raised the firm’s price target on BrightSpring Health (BTSG) to $55 from $50 and keeps a Buy rating on the shares as part of a broader research note previewing Q4 for Healthcare IT and Digital Health names. The firm is positive on the stock being among proven operators that have been performing consistently well, through many different cycles, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTSG:
- BrightSpring Health price target raised to $46 from $42 at TD Cowen
- BrightSpring Health price target raised to $46 from $40 at BMO Capital
- Wells says ‘Great Healthcare Plan’ lacks new onerous proposals
- BrightSpring Health price target raised to $45 from $42 at Mizuho
- BrightSpring Health price target raised to $43 from $39 at Wells Fargo